Skip to main content
Clinical Trials/NCT00452426
NCT00452426
Completed
Phase 3

Multi-center Pivotal Clinical Trial to Compare the Safety and Effectiveness of Procedural Sedation in GI Endoscopy: A Computer-Assisted Personalized Sedation (CAPS) Device Versus Current Standard of Care

Ethicon Endo-Surgery7 sites in 1 country1,000 target enrollmentMarch 2007

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Colonoscopy
Sponsor
Ethicon Endo-Surgery
Enrollment
1000
Locations
7
Primary Endpoint
Area Under the Curve for Oxygen Desaturation (AUCDesat)
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

Patients routinely receive sedation during a colonoscopy or upper endoscopy (esophagogastroduodenoscopy; EGD) procedure. Propofol is a sedative that can be used during these procedures. The purpose of this study is to determine if this CAPS device enables a physician/registered nurse (RN) team to safely and effectively administer propofol sedation during colonoscopy or EGD procedures relative to current sedation practices.

Registry
clinicaltrials.gov
Start Date
March 2007
End Date
October 2007
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ethicon Endo-Surgery

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years old
  • Able to comprehend, sign, and date the written informed consent form
  • English as primary language
  • Undergoing a non-emergent EGD or colonoscopy
  • Have taken nothing by mouth for a minimum of 6 hours prior to the study procedure
  • American Society of Anesthesiologists (ASA) Class I, II or III

Exclusion Criteria

  • Allergy or inability to tolerate study medications or components of study medications
  • Investigator anticipates greater than 45 minute procedure time due to known anatomical difficulty
  • Currently using a fentanyl patch
  • History of diagnosed sleep apnea
  • History of diagnosed gastroparesis
  • Baseline oxygen saturation \< 90% (room air)
  • Pregnant or nursing females
  • Body mass index (BMI) ≥ 35
  • Participation in a clinical trial within the past 30 days.

Outcomes

Primary Outcomes

Area Under the Curve for Oxygen Desaturation (AUCDesat)

Time Frame: From administration of initial drug dose until subject recovered from effects of sedation

AUCDesat measures desaturation as a function of incidence, magnitude, and duration. AUCDesat is the difference between the threshold and actual oxygen saturation measured every second. The total area below the 90% threshold is summated to determine AUCDesat in units of seconds\*percent.

Secondary Outcomes

  • Duration of Deep Sedation/General Anesthesia(From first dose until subject recovered from effects of sedation)
  • Patient Satisfaction(24-48 hours post sedation)
  • Clinician Satisfaction(Post procedure)
  • Recovery Time (From Sedation)(from "scope out" until first of two consecutive MOAA/S scores of 5)

Study Sites (7)

Loading locations...

Similar Trials